Scleroderma Therapeutics Market By Drug Class (Immunosuppressors, Phosphodiesterase 5 Inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, and Others), By Indication (Systemic and Localized), and By Region- Trends, Analysis, and Forecast till 2029

Scleroderma Therapeutics Market accounted for USD 1.7 Billion in 2019 and is estimated to be USD 3.2 Billion by 2029 and is anticipated to register a CAGR of 6.6%

Scleroderma is an autoimmune rheumatic disorder. It causes chronic hardening and tightening of the connective tissues and skin. However, the exact cause of Scleroderma is unknown, it involves overproduction of collagen. It might cause damage to the internal organs such as blood vessels, lungs, heart, kidney, and stomach. The incidences of scleroderma in women is four times greater as compared to men. Additionally, the prevalence is more frequent between 30 and 50 age group. 

The growing incidence and screening rates of Scleroderma is the major factor driving the growth of the scleroderma therapeutics market. According to the international reports from Japan and Britain, the incidence of systemic scleroderma is about 35 instances per 1 million adults. Scleroderma is a longstanding disease and needs a regular dose of drugs. Additionally, the increase in disposable income and growth in the awareness of preventive healthcare among the population is expected to increase the scleroderma therapeutics market.

Conversely, adverse effects of drugs, the stringent government guidelines, high healthcare cost, and diagnostic test of Scleroderma are major limitations for the growth of the market.

Nevertheless, ongoing R&D in the field of Scleroderma diagnosis and therapeutics is expected to create lucrative opportunities throughout the forecast period.

The scleroderma therapeutics market is segmented based on the drug class, indication, and region.

On the basis of the drug class, the scleroderma therapeutics market is segmented into immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, analgesics, and others. Based on the indication, the target market is classified into systemic and localized.

In the region, the scleroderma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the target market in 2019, owing to access to newly developed immunosuppressants along with favourable reimbursement scenario. Europe accounts for the lower share as compared to the U.S. majorly due to developed use of generics and biosimilars for off-label treatment of scleroderma. In developing regions, generics and OTC drugs are the backbone therapy for scleroderma and its indications. Even though experiencing price cuts, the Japan market has faster access to new orphan therapies. The projected growth in access to biosimilar and generic immunosuppressants will propel the growth in Latin America and MEA regions.

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2029.  For the purpose of this study, has segmented the scleroderma therapeutics market report based on drug class, indication, and region.

Scleroderma Therapeutics Market, By Drug Class:

• Immunosuppressors
• Phosphodiesterase 5 Inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Analgesics
• Others

Global Scleroderma Therapeutics Market, By Indication:

• Systemic
• Localized

Scleroderma Therapeutics Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • U.S.
  • Canada

The key players operating in the scleroderma therapeutics market include F. Hoffman La-Roche Ltd., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Akashi Therapeutics, Celgene Corp., Bayer AG, Seattle Genetics, Inc., Prometic Life Sciences, Inc., Emerald Health Pharmaceuticals, Kadmon Holdings, Inc., and Cytori Therapeutics, Inc. These companies focus on development strategies like product portfolio expansion, combinations and purchases and promotional activities to strengthen their presence in untapped market economies across the globe. For instance, in April 2020, Emerald Health Pharmaceuticals has launched a clinical trial evaluating EHP-101, its investigational cannabidiol-derived therapy, in adults with diffuse cutaneous systemic sclerosis (dcSSc).

• F. Hoffman La-Roche, Ltd.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Akashi Therapeutics
• Celgene Corp.
• Bayer AG
• Seattle Genetics, Inc.
• Prometic Life Sciences, Inc.
• Emerald Health Pharmaceuticals
• Kadmon Holdings, Inc.
• Cytori Therapeutics, Inc.